Show simple item record

dc.contributor.authorCapoluongo, Een_US
dc.contributor.authorEllison, Gen_US
dc.contributor.authorLópez-Guerrero, JAen_US
dc.contributor.authorPenault-Llorca, Fen_US
dc.contributor.authorLigtenberg, MJLen_US
dc.contributor.authorBanerjee, Sen_US
dc.contributor.authorSinger, Cen_US
dc.contributor.authorFriedman, Een_US
dc.contributor.authorMarkiefka, Ben_US
dc.contributor.authorSchirmacher, Pen_US
dc.contributor.authorBüttner, Ren_US
dc.contributor.authorvan Asperen, CJen_US
dc.contributor.authorRay-Coquard, Ien_US
dc.contributor.authorEndris, Ven_US
dc.contributor.authorKamel-Reid, Sen_US
dc.contributor.authorPercival, Nen_US
dc.contributor.authorBryce, Jen_US
dc.contributor.authorRöthlisberger, Ben_US
dc.contributor.authorSoong, Ren_US
dc.contributor.authorde Castro, DGen_US
dc.coverage.spatialUnited Statesen_US
dc.date.accessioned2018-02-16T11:40:19Z
dc.date.issued2017-06en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/29248130en_US
dc.identifierS0093-7754(17)30052-0en_US
dc.identifier.citationSemin Oncol, 2017, 44 (3), pp. 187 - 197en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1196
dc.identifier.eissn1532-8708en_US
dc.identifier.doi10.1053/j.seminoncol.2017.08.004en_US
dc.description.abstractThe approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of breast or ovarian cancer. Furthermore, testing of tumor samples to identify the estimated 3%-9% of patients with somatic BRCA1/2 mutations who, in addition to germline carriers, could benefit from PARPi therapy is also now being considered. This new testing paradigm poses some challenges, in particular the technical and analytical difficulties of analyzing chemically challenged DNA derived from formalin-fixed, paraffin-embedded specimens. The current manuscript reviews some of these challenges and technical recommendations to consider when undertaking BRCA1/2 testing in tumor tissue samples to detect both germline and somatic BRCA1/2 mutations. Also provided are considerations for incorporating genetic analysis of ovarian tumor samples into the patient pathway and ethical requirements.en_US
dc.format.extent187 - 197en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectBRCA1en_US
dc.subjectBRCA2en_US
dc.subjectOvarian canceren_US
dc.subjectTumor testingen_US
dc.subjectBRCA1 Proteinen_US
dc.subjectBRCA2 Proteinen_US
dc.subjectFemaleen_US
dc.subjectGenetic Testingen_US
dc.subjectGerm-Line Mutationen_US
dc.subjectHereditary Breast and Ovarian Cancer Syndromeen_US
dc.subjectHumansen_US
dc.subjectOvarian Neoplasmsen_US
dc.subjectPhthalazinesen_US
dc.subjectPiperazinesen_US
dc.subjectPoly(ADP-ribose) Polymerase Inhibitorsen_US
dc.subjectPractice Guidelines as Topicen_US
dc.titleGuidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-08-28en_US
rioxxterms.versionofrecord10.1053/j.seminoncol.2017.08.004en_US
rioxxterms.licenseref.startdate2017-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfSemin Oncolen_US
pubs.issue3en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume44en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorBanerjee, Susanaen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record